A Study to Assess Imaging Studies of Neurodegenerative and Related Disorders

Overview

About this study

The purpose of this study is to perform longitudinal assessments in patients with neurodegenerative and related disorders to better understand the underlying cause/s which will help with the development of future treatments and prognosis.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • All subjects will be over the age of 21.
  • Must have symptoms suggestive of a neurodegenerative and/or related disorder;  i.e., patients must have one or more neurological symptom that is insidious in onset and has worsened over time in nature.

Exclusion Criteria:

  • Subjects will be excluded if they have any concurrent illnesses that could account for all of their symptoms, such as traumatic brain injury, encephalitis, strokes or developmental syndromes.
  • Women that are pregnant or post-partum and breast-feeding will be excluded.
  • All women who can become pregnant must have a pregnancy test before the PET/CT scan.
  • Subjects will be excluded if they have any of the following genetic conditions which can increase the chance of cancer:
    • Cowden disease;
    • Lynch syndrome;
    • Hypogammaglobulinemia;
    • Wiskott-Aldrich syndrome;
    • Down’s syndrome.
  • Subjects will be excluded from undergoing the MRI if it is contraindicated (metal in head, cardiac pace maker, etc), if there is severe claustrophobia, if there are conditions that may confound brain imaging studies (e.g., structural abnormalities, including subdural hematoma, intracranial neoplasm or large cortical infarcts), or if they are medically unstable or are on medications that might affect brain structure or metabolism (e.g., chemotherapy).

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Keith Josephs, M.D.

Contact us for the latest status

Contact information:

Sarah Boland CCRP

(507) 284-3863

Boland.Sarah@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20493021

Mayo Clinic Footer